Expanding Endpoint Analysis with Flow Cytometry

Better Together: Expanding Endpoint Analysis with Flow Cytometry

How the SauveBio and Biomere partnership is streamlining preclinical workflows.

In the complex world of drug development, the transition between in vivo studies and downstream analysis is often where logistical headaches happen. Samples degrade, timelines drag, and coordination between vendors can become a full-time job.

At SauveBio, we believe that workflow should be seamless.

We are excited to share a recent conversation featuring our very own Hannah Sheehan, who sat down with the team at Biomere to discuss exactly how we are solving these challenges. In this new podcast episode, we dive deep into the “symbiotic” partnership between our two organizations and what it means for the future of endpoint analysis.

The “Symbiotic” Partnership

As discussed in the episode, the collaboration between SauveBio and Biomere is designed to bridge the gap between the vivarium and the flow cytometry lab.

By integrating SauveBio’s advanced cell sorting and flow cytometry capabilities directly with Biomere’s preclinical resources, we offer our clients a unified solution. This means samples don’t just “go to a lab”, they move through a coordinated pipeline designed to maximize cell viability and data quality.

What We Cover in the Episode

If you are involved in preclinical research, immunology, or drug discovery, this conversation is for you. Hannah and Anjli break down:

• The Role of Flow Cytometry: Why high-parameter sorting is becoming the gold standard for endpoint analysis in modern therapeutics.
• Custom Applications: How we tailor our sorting strategies to fit specific study goals, whether it’s rare cell isolation or broad immunophenotyping.
• The Client Experience: What “expanded services” actually looks like for the researchers we support.

Watch the Full Conversation

Ready to see how we are redefining the preclinical workflow? Watch the full podcast episode below to hear Hannah Sheehan and the Biomere team discuss the science, the strategy, and the future of our partnership.